GlaxoSmithKline: Making an impact on emerging markets

Authored by Abbas Hussain, Senior Partner, C-Bridge Capital

Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of  emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Leadership in Times of Radical Change

There are significant changes underway in the UK’s water industry. Phil Aspin, CFO of United Utilities, talks to Criticaleye about adaptability, investment and his own personal journey as a finance leader. A...


Click here to download this insight

Cutting Through Complexity as CEO

Nick Elliott, CEO of AWE Nuclear Security Technologies, talks to Criticaleye’s Jacob Ambrose Willson about why the biggest, most complex projects are the most rewarding. A common theme that runs throughout...


HR Leaders At The Top Table: Robert Chong on the Evolving Role of the CPO

Robert Chong, Senior Advisor for Sembcorp Industries and a Criticaleye Board Mentor speaks to Criticaleye Senior Editor Bridgette Hall about the evolving role of the CHRO in Asia and if HR leaders are adapting and eq...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 206




London Stock Exchange Group LACE Partners E.ON UK NatWest Group NATS British Land Drax Group plc Hitachi Solutions Mayborn Group Lightsource bp Legal & General Global Payments Rolls-Royce GlaxoSmithKline plc AlixPartners Stream